Browsing Tag
AREXVY
3 posts
Clover Biopharmaceuticals receives FDA clearance for RSV vaccine trial, expands respiratory disease research
Clover Biopharmaceuticals advances RSV vaccine research with FDA-approved SCB-1019 trials, targeting revaccination gaps and combination immunization strategies.
March 24, 2025
Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk
In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline’s Arexvy vaccine to…
November 7, 2024
FDA extends approval for GSK’s RSV vaccine, AREXVY, to adults aged 50-59 at increased risk
The U.S. Food and Drug Administration (FDA) has officially broadened the age indication for GSK plc’s (LSE/NYSE: GSK)…
June 9, 2024